News
-
-
-
Bubs HealthOne deal
Friday | Jul 21 2017LISTED organic baby food and infant milk formula producer Bubs Australia Limited has entered into a distribution and field marketing services agreement with HealthOne which will provide sales and key account services to pharmacies across Australia.
-
Nicotine & OC consult
Friday | Jul 21 2017NEW Zealand's Pharmaceutical Management Agency, PHARMAC, is calling on pharmacists and other stakeholders to provide input relating to proposals around nicotine replacement therapy (NRT) and emergency contraceptive pill (levonorgestrel tablets) (ECP).
-
FDA hep C drug nod
Friday | Jul 21 2017THE US Food and Drug Administration (FDA) has approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis.
-
Free pain conference
Friday | Jul 21 2017WESTERN Sydney community pharmacists, people living with chronic pain and other health professionals are invited to participate in a free conference at Westmead Hospital next week as part of National Pain Week.
-
Caffeine study hailed
Friday | Jul 21 2017AUSTRALIAN pharmaceutical manufacturer Phebra has welcomed the findings of a new study demonstrating the sustained benefits of giving neonatal caffeine to pre-term babies suffering breathing difficulties.
-
Maxigesic expansion
Friday | Jul 21 2017AFT Pharmaceuticals' Maxigesic painkiller product is now licensed in 124 countries worldwide, after the formalisation of an agreement with European pharmaceutical group Amicus SA Switzerland in three regions: the Baltics (Latvia, Estonia and Lithuania); Central Eastern Europe (Czech Republic, Hungary, Bulgaria, Romania and Slovakia); and most of the Balkans (Croatia, Slovenia, Serbia, Montenegro, Bosnia and Macedonia).
-
French codeine ban
Friday | Jul 21 2017FRENCH Health Minister Agnes Buzin last week announced that medications containing codeine would be placed on the country's list of prescription-only drugs.
-
PDL reiterates methotrexate alert
Friday | Jul 21 2017PHARMACEUTICAL Defence Limited has confirmed that despite the well-recognised and publicised dangers when dispensing methotrexate incorrectly, it continues to receive reports of error with this drug.
